PDL BioPharma (PDLI) Reports In-Line Q3 EPS

November 3, 2016 6:00 PM EDT

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

PDL BioPharma (NASDAQ: PDLI) reported Q3 EPS of $0.08, in-line with the analyst estimate of $0.08. Revenue for the quarter came in at $53.6 million versus the consensus estimate of $50.69 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment